MDMA Reimbursement Conference Notes 2017

MDMA Reimbursement Conference speakers provide highlights from their sessions at the 2017 forum

Perspectives on Medical Reimbursement By JR Associates Over the years, our consultants have developed strong, productive working relationships with many influential medical and biotech industry associations, including the Medical Device Manufacturers Association (MDMA). One of the highlights of MDMA’s annual events calendar is its Coverage, Reimbursement and Health Policy Conference, where our leaders have participated as featured…

Read More »

Medical Device Reimbursement: ReGARDD Forum Notes

Perspectives on Medical Reimbursement By JR Associates What should medical device researchers know about premarket FDA submissions? And what should they understand about reimbursement in early stages of product development?  These core questions inspired the first educational seminar hosted by ReGARDD (Regulatory Guidance for Academic Research of Drugs and Devices) in April 2017, where our…

Read More »

Medical Device Innovation and Reimbursement: MDMA 2016 Conference Notes

Read notes from MDMA Reimbursement Conference presentations 2016

Perspectives on Medical Reimbursement By JR Associates Through the years, our consultants have become popular as featured speakers at a variety of prestigious medical technology forums. But the highlight of our annual events calendar is always the MDMA Coverage, Reimbursement & Health Policy Conference. It is deeply rewarding to connect directly with medical device professionals and discuss critical…

Read More »

MDMA Reimbursement Conference Notes: 2015

Perspectives on Medical Reimbursement By JR Associates (Editor’s Note: Our leaders spoke again at the 2016 MDMA Reimbursement Conference on November 16-17 in Baltimore. As always, it was rewarding to reconnect with medical device professionals and explore timely reimbursement issues. We’ll be recapping those sessions on the blog before the end of December. ) For years, our consultants…

Read More »

What Should Life Sciences Startups Know About Reimbursement?

Reimbursement for Life Sciences Startups - JR Assocates VP Global Health Policy Jo Ellen Surzberg at Harvard Innovation Lab

Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…

Read More »

Autism Investment Conference Session Notes

Jo Ellen Slurzberg_Reimbursement Strategies Autism Investment Conference

Perspectives on Medical Reimbursement By JR Associates Continuing its efforts to cultivate a marketplace of innovation that better serves those affected by autism, Autism Speaks recently hosted its third annual Autism Investment Conference in Boston. Our VP of Global Health Policy, Jo Ellen Slurzberg, was among the nearly 200 investors, entrepreneurs, healthcare advocates and corporate…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How can medical technology innovators leverage reimbursement strategy across markets? Advice from JR Associates consultants

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

Bundled Payments: Implications for Medical Device & Drug/Biologic Companies

Bundled Payments for Medical Technology

Perspectives on Medical Reimbursement By JR Associates Recently, the trade press and mainstream news have been paying a lot of attention to bundled payments. Stories have focused primarily on how this shift in medical reimbursement will affect patients, providers and payers. Payers and provider networks are creating internal systems to identify the cost of treating…

Read More »